List of works - Netta Mäkinen

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.

scientific article published on 7 June 2017

Characterization of uterine leiomyomas by whole-genome sequencing.

scientific article published on 5 June 2013

Clonally related uterine leiomyomas are common and display branched tumor evolution.

scientific article published on 10 May 2015

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

scientific article published on 18 February 2016

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers

scientific article published on 21 March 2019

Exome-wide somatic mutation characterization of small bowel adenocarcinoma.

scientific article published on 9 March 2018

Genomics of uterine leiomyomas: insights from high-throughput sequencing

scientific article

Global metabolomic profiling of uterine leiomyomas.

scientific article

Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers

scientific article

Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas

scientific article published on 13 November 2018

MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.

scientific article published on December 2011

MED12 exon 2 mutations in histopathological uterine leiomyoma variants

scientific article published on 27 February 2013

MED12 mutation frequency in unselected sporadic uterine leiomyomas.

scientific article published on 6 August 2014

MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.

scientific article published on 17 May 2016

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas

scientific article

Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.

scientific article

Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas

scientific article

Parity associates with chromosomal damage in uterine leiomyomas

scientific article published on 14 September 2021

Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry

scientific article

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

scientific article published on 18 September 2015

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

scientific article

Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.

scientific article

List of works by Netta Mäkinen

Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.

Characterization of uterine leiomyomas by whole-genome sequencing.

Clonally related uterine leiomyomas are common and display branched tumor evolution.

Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12.

Exome and immune cell score analyses reveal great variation within synchronous primary colorectal cancers

Exome-wide somatic mutation characterization of small bowel adenocarcinoma.

Genomics of uterine leiomyomas: insights from high-throughput sequencing

Global metabolomic profiling of uterine leiomyomas.

Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers

Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas

MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.

MED12 exon 2 mutations in histopathological uterine leiomyoma variants

MED12 mutation frequency in unselected sporadic uterine leiomyomas.

MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.

MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas

Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas.

Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas

Parity associates with chromosomal damage in uterine leiomyomas

Somatic MED12 Nonsense Mutation Escapes mRNA Decay and Reveals a Motif Required for Nuclear Entry

Somatic MED12 mutations in prostate cancer and uterine leiomyomas promote tumorigenesis through distinct mechanisms.

Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.

Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.